NHS approves breakthrough drug that can delay type 1 diabetes for years

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleThe National Institute for Health and Care Excellence (NICE) has approved teplizumab (Tzield) for use in the NHS, marking a significant advancement in type 1 diabetes treatment. This first-of-its-kind therapy can delay the onset of symptomatic type 1 diabetes by an average of nearly three years, offering patients valuable time before needing aggressive management. Teplizumab is approved for children aged eight and over and adults who have early-stage type 1 diabetes before symptoms appear, training the immune system to prevent it from attacking pancreatic cells. The treatment involves a one-off course of daily infusions over 14 days, with an estimated 1,100 people eligible in the first year. Diabetes UK has hailed the approval as a “landmark moment” and the “start of a new age of type 1 diabetes treatment,” with ongoing studies to screen and identify eligible individuals. In fullExperts hail ‘new age of diabetes treatment’ as drug approved on NHSThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in

Raccontata dadailymail.comindependent.co.uktheguardian.comnews.yale.edu